Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tavokinogene telseplasmid plus electroporation with pembrolizumab in anti-PD-1 progressing melanoma
2019-001409-26Phase 2Completed
- Sponsor
- OncoSec Medical
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tavokinogene telseplasmid and pembrolizumab in melanoma, sponsored by OncoSec Medical. Primary endpoint: Overall response rate. Started Jul 2019; status: completed.
02
Drugs
tavokinogene telseplasmidpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-001409-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001409-26.